# EDGAR Filing Document

**Accession Number:** 0001834051
**File Stem:** 0001493152-26-011858
**Filing Date:** 2026-3
**Character Count:** 7437
**Document Hash:** 96bbcff0466113819fd49cfef08219bb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-011858.hdr.sgml**: 20260320

**ACCESSION NUMBER**: 0001493152-26-011858

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260320

**DATE AS OF CHANGE**: 20260320

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Salva Francisco D.
- **CENTRAL INDEX KEY:** 0001834051

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41705
- **FILM NUMBER:** 26778622

**MAIL ADDRESS:**
- **STREET 1:** 4500 GREAT AMERICA PKWY
- **STREET 2:** STE. 100 #29
- **CITY:** SANTA CLARA
- **STATE:** CA
- **ZIP:** 95054
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Azitra, Inc.
- **CENTRAL INDEX KEY:** 0001701478
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 464478536
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 21 BUSINESS PARK DRIVE, SUITE 6
- **CITY:** BRANFORD
- **STATE:** CT
- **ZIP:** 06405
- **BUSINESS PHONE:** (203) 489-0183

**MAIL ADDRESS:**
- **STREET 1:** 21 BUSINESS PARK DRIVE, SUITE 6
- **CITY:** BRANFORD
- **STATE:** CT
- **ZIP:** 06405

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Azitra Inc
- **DATE OF NAME CHANGE:** 20170320

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Salva Francisco D.<br><sub>(Last) (First) (Middle)</sub><br>21 BUSINESS PARK DRIVE<br><sub>(Street)</sub><br>BRANFORD, CT 06405<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President and CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Azitra, Inc. [ AZTR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series A Convertible Non-Redeemable Preferred Stock | $0.123 | 2026-03-18 |  | P |  | 500 |  | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 4064050 | <sup>(1)</sup> | 500 | D |  |
| Series B Warrants | $0.123 | 2026-03-18 |  | P |  | 4064050 |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 4064050 | <sup>(1)</sup> | 4064050 | D |  |
| Series C Warrants | $0.123 | 2026-03-18 |  | P |  | 4064050 |  | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 4064050 | <sup>(3)</sup> | 4064050 | D |  |

---

### Footnotes:

(1) The Series A Preferred Stock has stated value of $1,000.00 per share. Each share of Series A Preferred Stock automatically converts into 8,128.1 shares of Common Stock, subject to adjustment from time to time in accordance with its Certificate of Designations, Preferences, as of 5:00 p.m. Eastern time on the 1st business day after the date that the Issuer's stockholders have approved each of (A) an increase in the number of authorized shares of the Issuer's Common Stock to enable the Issuer to issue all of the shares of Common Stock that are issuable upon the conversion of the Series A Preferred Stock and (B) the conversion of the Series A Preferred Stock into Common Stock in accordance with the listing rules of the applicable trading market, and subject to the Issuer filing an amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware evidencing such stockholder approval. The Series A Preferred Stock has no expiration date.

(2) The Series B Warrants are exercisable upon stockholder approval and will terminate 18 months following the date of stockholder approval.

(3) The Series C Warrants are exercisable upon stockholder approval and will terminate, subject to certain exceptions, upon the 30th calendar day following the date on which Azitra, Inc. publicly announces data from its planned human cosmetic study testing the effect of the filaggrin technology.

**Signature:** /s/ Francisco D. Salva  
**Date:** 2026-03-20

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**